Abstract | PURPOSE: PATIENTS AND METHODS: Ninety-nine children between one and 21 years of age with recurrent brain tumors were randomly assigned to treatment with intravenous etoposide 150 mg/M2, with or without mannitol 15 gm/M2, daily for five days every three weeks for one year or until disease progression or death. Computerized tomographic (CT) or magnetic resonance image (MRI) scans, obtained after three cycles of therapy, were compared with pre- therapy scans. Scans were centrally reviewed. RESULTS: CONCLUSION:
|
Authors | N L Kobrinsky, R J Packer, J M Boyett, P Stanley, T Shiminski-Maher, J C Allen, J H Garvin, D J Stewart, J L Finlay |
Journal | Journal of neuro-oncology
(J Neurooncol)
Vol. 45
Issue 1
Pg. 47-54
( 1999)
ISSN: 0167-594X [Print] United States |
PMID | 10728909
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antineoplastic Agents, Phytogenic
- Mannitol
- Etoposide
|
Topics |
- Adolescent
- Antineoplastic Agents, Phytogenic
(adverse effects, therapeutic use)
- Brain Neoplasms
(diagnosis, drug therapy)
- Child
- Drug Therapy, Combination
- Etoposide
(adverse effects, therapeutic use)
- Female
- Humans
- Injections, Intravenous
- Magnetic Resonance Imaging
- Male
- Mannitol
(adverse effects, therapeutic use)
- Neoplasm Recurrence, Local
(drug therapy)
- Survival Analysis
- Treatment Failure
|